January 1, 2011Open Access

(-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 бvia Stat3 in gastric cancer

Key Points

Key points are not available for this paper at this time.

Abstract

EGCG inhibits IL-6-induced VEGF expression and angiogenesis via suppressing Stat3 activity in gastric cancer, which has provided a novel mechanistic insight into the anti-angiogenic activity of EGCG.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Baohe Zhu (Sat,) studied this question.

synapsesocial.com/papers/69de98905e582bd3c5e93b69 https://doi.org/https://doi.org/10.3748/wjg.v17.i18.2315

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Targeting Stat3 in cancer therapy2005 · 282 citations
2Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells2003 · 167 citations
3Interleukin-6 Increases Vascular Endothelial Growth Factor and Angiogenesis in Gastric Carcinoma2004 · 25 citations
4Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma2008 · 92 citations
5(–)‐Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor–vascular endothelial growth factor receptor axis2009 · 102 citations

Perguntar à IA

Bookmark

View Full Paper